TP53 缺失通过上调 NF-κB-IFN-β-MHC-Ia 信号促进骨肉瘤对 NK 细胞的抵抗
TP53 Loss Elevates NF-κB-IFN-β-MHC-Ia Signaling to Promote NK Cell Resistance in Osteosarcoma.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Effects of indoleamine 2, 3-dioxygenase (IDO) silencing on immunomodulatory function and cancer-promoting characteristic of adipose-derived mesenchymal stem cells (ASCs).
Effects of indoleamine 2, 3-dioxygenase (IDO) silencing on immunomodulatory function and cancer-promoting characteristic of adipose-derived mesenchymal stem cells (ASCs).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
吲哚胺2, 3-双加氧酶(IDO)催化色氨酸分解代谢,介导免疫调节功能,并由间充质干细胞等基质细胞释放。本研究旨在探讨IDO沉默对脂肪源性间充质干细胞(ASCs)免疫抑制功能、T细胞表型以及肿瘤细胞增殖/迁移的影响。从健康女性脂肪组织中分离的ASCs转染IDO-siRNA。采用qRT-PCR检测ASCs中作为免疫调节因子的Galectin-3、转化生长因子-1、肝细胞生长因子和白细胞介素-10。分别通过流式细胞术和qRT-PCR评估与IDO沉默ASCs共培养的外周血淋巴细胞(PBLs)中T细胞表型、干扰素-和白细胞介素-17的表达。
采用划痕实验评估MDA-MB-231细胞系的增殖/迁移。与对照组相比,IDO沉默ASCs中Galectin-3上调(p 0.05),而肝细胞生长因子下调(p 0.05)。与IDO沉默ASCs共培养的PBLs中调节性T细胞受到抑制;此外,与scramble组相比,与IDO沉默ASCs共培养的PBLs中辅助性T细胞2减少。IDO沉默ASCs导致PBLs中干扰素-过表达,但白细胞介素-17下调。与未转染ASCs的条件培养基(p < 0.01)和scramble转染ASCs的条件培养基(p < 0.05)相比,暴露于IDO沉默ASCs条件培养基后,MDA-MB-231的增殖/迁移受到抑制。
结果表明,IDO沉默ASCs抑制免疫细胞和促进肿瘤细胞增殖/迁移的能力减弱。IDO抑制可能被用作癌症治疗的一种策略。同时阻断免疫调节剂与IDO抑制剂可能对提高免疫为基础癌症疗法的效率显示出更多效果。
Indoleamine 2, 3-dioxygenase (IDO) catabolizes tryptophan, mediates immunomodulatory functions, and is released by stromal cells such as mesenchymal stem cells. The aims of this study were to investigate the effects of IDO silencing on immunosuppressive function of adipose-derived mesenchymal stem cells (ASCs), T cells phenotype, and the proliferation/migration of tumor cells. ASCs isolated from adipose tissues of healthy women were transfected with IDO-siRNA. Galectin-3, transforming growth factor- 1, hepatocyte growth factor, and interleukin-10 as immunomodulators were measured in ASCs using qRT-PCR. T cells phenotype, interferon- , and interleukin-17 expression were evaluated in peripheral blood lymphocytes (PBLs) cocultured with IDO silenced-ASCs by flow cytometry and qRT-PCR, respectively. Scratch assay was applied to assess the proliferation/migration of MDA-MB-231 cell line. Galectin-3 was upregulated (p 0.
05) while hepatocyte growth factor was downregulated (p 0. 05) in IDO-silenced ASCs compared to control groups. Regulatory T cells were inhibited in PBLs cocultured with IDO-silenced ASCs; also T helper2 was decreased in PBLs cocultured with IDO-silenced ASCs relative to the scramble group. IDO-silenced ASCs caused interferon- overexpression but interleukin-17 downregulation in PBLs. The proliferation/migration of MDA-MB-231 was suppressed after exposing to condition media of IDO-silenced ASCs compared with condition media of untransfected (p < 0.
01) and scramble-transfected ASCs (p < 0. 05). The results exhibited the weakened capacity of IDO-silenced ASCs for suppressing the immune cells and promoting the tumor cells' proliferation/migration. IDO suppression may be utilized as a strategy for cancer treatment. Simultaneous blocking of immunomodulators along with IDO inhibitors may show more effects on boosting the efficiency of immune-based cancer therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。